No Data
Express News | China Resources Pharmaceutical - Kpc Pharmaceuticals Proposed to Distribute Cash Dividend of RMB3.00 per Share
Express News | China Resources Pharmaceutical - FY Revenue for Kpc Pharmaceuticals RMB8.40 Bln
CHINARES PHARMA: ANNOUNCEMENTPRINCIPAL FINANCIAL INFORMATION OFKPC FOR THE YEAR ENDED31 DECEMBER 2024
CHINARES PHARMA (03320.HK) will hold a Board of Directors meeting on March 26 to approve the annual performance.
Gelonghui reported on March 11 that CHINARES PHARMA (03320.HK) announced that it will hold a Board of Directors meeting on March 26, 2025, aiming to consider and approve (if applicable) (i) the annual performance of the company and its subsidiaries for the year ending December 31, 2024, and its publication; and (ii) the proposal for the declaration of a final dividend (if any).
CHINARES PHARMA: DATE OF BOARD MEETING
National People's Congress representative, Zhao Jing of Shandong Buchang Pharmaceuticals: "The 'AI+' is reaching a critical point of explosion. It is recommended to utilize AI to empower the inheritance and innovation of Traditional Chinese Medicine | Two
① Zhao Jing, a representative of the National People's Congress and Vice Director of Shandong Buchang Pharmaceuticals, brought the proposal "Utilizing AI to Empower the Inheritance and Innovation of Traditional Chinese Medicine and Build a New Pattern of Development for Traditional Chinese Medicine with 'Asia Vets + Technology'" to this year's Two Sessions, aiming to promote the intelligent upgrade of the Traditional Chinese Medicine industry through AI technology. ② Zhao Jing stated that the development of large models like DeepSeek has indeed pushed the integration of Traditional Chinese Medicine and AI to a critical point of explosion.
